ARHGAP29

Across TCGA pan-cancer cohorts, ARHGAP29 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ARHGAP29 data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARHGAP29 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ARHGAP29 expression acts as an unfavorable survival marker.

HNSC, PDAC, and LUAD are the cancer types where ARHGAP29 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	III,IV	0.743	0.955	.009	15	view →
PDAC	OS	Median	All	0.455	0.605	.027	9	view →
LUAD	OS	Quartile	II,III,IV	0.314	0.715	.010	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ARHGAP29–HNSC (OS)

Open the HNSC breakdown →